- Home
- Publications
- Publication Search
- Publication Details
Title
Etanercept for the treatment of rheumatoid arthritis
Authors
Keywords
-
Journal
Immunotherapy
Volume 10, Issue 6, Pages 433-445
Publisher
Future Medicine Ltd
Online
2018-02-27
DOI
10.2217/imt-2017-0155
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial
- (2017) Roy Fleischmann et al. LANCET
- Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis
- (2017) Peter C. Taylor et al. NEW ENGLAND JOURNAL OF MEDICINE
- Systematic review and meta-analysis: pharmacogenetics of anti-TNF treatment response in rheumatoid arthritis
- (2017) S Bek et al. PHARMACOGENOMICS JOURNAL
- Risk of tuberculosis in patients treated with TNF-α antagonists: a systematic review and meta-analysis of randomised controlled trials
- (2017) Zheng Zhang et al. BMJ Open
- Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician
- (2017) Robert Moots et al. Current Rheumatology Reports
- EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry
- (2017) Tanja Schjødt Jørgensen et al. PLoS One
- The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study
- (2017) Robert J. Moots et al. PLoS One
- Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration
- (2016) Lisa Marshall et al. ANNALS OF THE RHEUMATIC DISEASES
- Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required
- (2016) Robert J Moots et al. ANNALS OF THE RHEUMATIC DISEASES
- Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo: Table 1
- (2016) Paul Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Difference between Enbrel and Benepali treatment groups in ‘hepatobiliary disorders’
- (2016) Morton Scheinberg et al. ANNALS OF THE RHEUMATIC DISEASES
- A phase III, multicentre, randomised, double-blind, active-controlled, parallel-group trial comparing safety and efficacy of HD203, with innovator etanercept, in combination with methotrexate, in patients with rheumatoid arthritis: the HERA study
- (2016) Sang-Cheol Bae et al. ANNALS OF THE RHEUMATIC DISEASES
- THU0150 Long-Term Safety and Efficacy of SB4 (Etanercept Biosimilar) in Patients with Rheumatoid Arthritis: Comparison between Continuing SB4 and Switching from Etanercept Reference Product To SB4
- (2016) P. Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial
- (2016) Gerd R Burmester et al. ANNALS OF THE RHEUMATIC DISEASES
- Tumour necrosis factor inhibition versus rituximab for patients with rheumatoid arthritis who require biological treatment (ORBIT): an open-label, randomised controlled, non-inferiority, trial
- (2016) Duncan Porter et al. LANCET
- Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study
- (2016) Josef S Smolen et al. LANCET
- A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy
- (2015) Paul Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Rates of Serious Infections and Malignancies Among Patients with Rheumatoid Arthritis Receiving Either Tumor Necrosis Factor Inhibitor or Rituximab Therapy
- (2015) K. J. Aaltonen et al. JOURNAL OF RHEUMATOLOGY
- Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials
- (2015) Vibeke Strand et al. ARTHRITIS RESEARCH & THERAPY
- THU0526 Tocilizumab is Less Dependent than Adalimumab on Supplementary Effects of Methotrexate for Immunoregulation: A Biomap® Profiling Study
- (2014) A. O'Mahony et al. ANNALS OF THE RHEUMATIC DISEASES
- Risk of tuberculosis, serious infection and lymphoma with disease-modifying biologic drugs in rheumatoid arthritis patients in Taiwan
- (2014) Ying-Ming Chiu et al. International Journal of Rheumatic Diseases
- Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial
- (2014) Hideto Kameda et al. Modern Rheumatology
- Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab
- (2013) Joachim Listing et al. ANNALS OF THE RHEUMATIC DISEASES
- Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis
- (2013) Paul Emery et al. ANNALS OF THE RHEUMATIC DISEASES
- Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial
- (2013) Cem Gabay et al. LANCET
- Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis
- (2013) Pauline A. van Schouwenburg et al. Nature Reviews Rheumatology
- Treatment of rheumatoid arthritis with etanercept with reference to disease-modifying anti-rheumatic drugs: long-term safety and survival using prospective, observational data
- (2013) C. L. Morgan et al. RHEUMATOLOGY
- Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs
- (2013) Daniel H. Solomon et al. SEMINARS IN ARTHRITIS AND RHEUMATISM
- Immunogenicity of Monoclonal Antibodies Against Tumor Necrosis Factor Used in Chronic Immune-Mediated Inflammatory Conditions
- (2013) Jose Ramon Maneiro et al. JAMA Internal Medicine
- The influence of anti-TNF therapy upon incidence of keratinocyte skin cancer in patients with rheumatoid arthritis: longitudinal results from the British Society for Rheumatology Biologics Register
- (2012) Louise K Mercer et al. ANNALS OF THE RHEUMATIC DISEASES
- Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseases
- (2012) Kevin Haynes et al. ARTHRITIS AND RHEUMATISM
- Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study
- (2012) Michael E. Weinblatt et al. ARTHRITIS AND RHEUMATISM
- The State of the Art in the Development of Biosimilars
- (2012) Mark McCamish et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Systematic Review and Meta-Analysis of the Efficacy and Safety of Existing TNF Blocking Agents in Treatment of Rheumatoid Arthritis
- (2012) Kalle J. Aaltonen et al. PLoS One
- Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients
- (2011) A Jamnitski et al. ANNALS OF THE RHEUMATIC DISEASES
- Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: A meta-analysis of randomized controlled trials
- (2011) Andrew E. Thompson et al. ARTHRITIS AND RHEUMATISM
- Risk of non-melanoma skin cancer in a national cohort of veterans with rheumatoid arthritis
- (2011) Wassila Amari et al. RHEUMATOLOGY
- Rheumatoid arthritis
- (2010) David L Scott et al. LANCET
- Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry
- (2009) X Mariette et al. ANNALS OF THE RHEUMATIC DISEASES
- Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
- (2009) W. G. Dixon et al. ANNALS OF THE RHEUMATIC DISEASES
- Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry
- (2009) Merete Lund Hetland et al. ARTHRITIS AND RHEUMATISM
- A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview
- (2009) J. A. Singh et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Herpes Zoster Risk Factors in a National Cohort of Veterans with Rheumatoid Arthritis
- (2009) Jay R. McDonald et al. CLINICAL INFECTIOUS DISEASES
- Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
- (2008) B Combe et al. ANNALS OF THE RHEUMATIC DISEASES
- Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
- (2008) J Askling et al. ANNALS OF THE RHEUMATIC DISEASES
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now